Overview: CD33 Flow Cytometry TestIntroduction: The CD33 Flow Cytometry Test detects CD33 markers to diagnose acute myeloid leukemia, causing fatigue or easy bruising. Following 2023 ASH guidelines, it uses flow cytometry for high specificity, aiding in cancer screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in hematology for patients with suspected acute myeloid leukemia.
Other Names: CD33 Flow Assay, Myeloid Marker Test.
FDA Status: Laboratory-developed test (LDT), meeting hematology standards for diagnostic accuracy.
Historical Milestone: CD33 testing began in the 1990s with leukemia research. Flow cytometry emerged in the 2000s, improving accuracy for AML diagnosis.
Purpose: Diagnoses acute myeloid leukemia, guides treatment, and monitors CD33 markers in patients with fatigue or easy bruising.
Test Parameters: 1. CD33
Pretest Condition: No fasting required. Collect whole blood or bone marrow at any time. Report symptoms like fatigue or easy bruising, and list medications.
Specimen: 2-5 mL whole blood (EDTA) or 2-5 mL bone marrow (EDTA). Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document fatigue, easy bruising, or history of acute myeloid leukemia. Include current medications, especially chemotherapeutics.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for cancer therapy.
Procedural Considerations: Uses flow cytometry to detect CD33 markers. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Poor sample quality or low cell yield can affect results. Non-malignant conditions may express CD33.
Clinical Significance: Positive CD33 expression suggests acute myeloid leukemia, prompting targeted therapy. Negative results may require additional marker testing.
Specialist Consultation: Consult a hematologist or oncologist for result interpretation.
Additional Supporting Tests: Bone marrow biopsy, other flow cytometry markers (e.g., CD13, CD34), or cytogenetic testing to confirm AML.
Test Limitations: Non-specific expression may occur in non-malignant conditions. Results require clinical correlation.
References: ASH Leukemia Guidelines, 2023; Blood, Arber DA, 2022.
